Skip to main content
Clinical Trials/EUCTR2011-004420-35-PT
EUCTR2011-004420-35-PT
Active, not recruiting
Not Applicable

A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects

Gilead Sciences, Inc.0 sites480 target enrollmentAugust 7, 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Human Immunodeficiency Virus-1 (HIV-1) Infections
Sponsor
Gilead Sciences, Inc.
Enrollment
480
Status
Active, not recruiting
Last Updated
11 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 7, 2013
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Subjects must meet all of the following inclusion criteria to be eligible for participation in this study.
  • Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures.
  • HIV\-1 infected subjects regardless of race or ethnicity
  • Use of one of the following taken as a stable, continuous, NRTI\-containing ARV regimen for \= 3 years are allowed (withinclass change of agents other than TDF within 3 years of study entry
  • are permitted as specified):
  • \- a TDF plus PI/r\-containing regimen, including subjects who switched from one TDF plus PI/r regimen to another TDF plus PI/r regimen
  • \- a TDF plus non\-PI/r\-containing regimen, including subjects who switched from a TDF plus non\-PI/r
  • regimen to another TDF plus non\-PI/r regimen
  • \- a Non\-TDF NRTI plus a PI/r \-containing regimen, including subjects who switched from one non\-TDF
  • NRTI plus PI/r regimen to another non\-TDF NRTI regimen plus PI/r regimen

Exclusion Criteria

  • Subjects who meet any of the following exclusion criteria are not to be enrolled in this study.
  • Have a contraindication to dual\-energy X\-ray absorptiometry (DEXA) scans
  • Have a history of osteoporosis before initiating highly active antriretroviral therapy

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A Study of Bone Mineral Density in HIV Infected SubjectsHuman Immunodeficiency Virus-1 (HIV-1) InfectionsMedDRA version: 14.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Immune System Diseases [C20]
EUCTR2011-004420-35-IEGilead Sciences, Inc.480
Active, not recruiting
Not Applicable
A Study of Bone Mineral Density in HIV Infected SubjectsHuman Immunodeficiency Virus-1 (HIV-1) InfectionsMedDRA version: 14.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Immune System Diseases [C20]
EUCTR2011-004420-35-NLGilead Sciences, Inc.480
Active, not recruiting
Not Applicable
A Study of Bone Mineral Density in HIV Infected SubjectsHuman Immunodeficiency Virus-1 (HIV-1) InfectionsMedDRA version: 14.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Immune System Diseases [C20]
EUCTR2011-004420-35-BEGilead Sciences, Inc.480
Active, not recruiting
Not Applicable
A Study of Bone Mineral Density in HIV Infected SubjectsHuman Immunodeficiency Virus-1 (HIV-1) InfectionsMedDRA version: 14.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Immune System Diseases [C20]
EUCTR2011-004420-35-ITGilead Sciences, Inc.480
Active, not recruiting
Not Applicable
A Study of Bone Mineral Density in HIV Infected SubjectsHuman Immunodeficiency Virus-1 (HIV-1) InfectionsMedDRA version: 14.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Immune System Diseases [C20]
EUCTR2011-004420-35-ESGilead Sciences, Inc.480